Rebekah Jordan fired out some quick Q&As with the Verseon team to shed light on their PKI treatment for diabetic vision loss, its advantages over injection treatments as well as its effectiveness long term.
Verseon recently announced that the European Patent Office granted intellectual property protection covering novel chemical matter including plasma kallikrein inhibitors (PKIs) – a potential treatment for diabetic rectinopathy (DR).